Navigation Links
New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
Date:4/29/2009

term outcomes. Drug exposure was measured as the medication possession ratio (MPR) defined as the actual time the patient received therapy divided by the total time possible before a negative outcome was reached (or at data censor). A statistical method called recursive partitioning was then used to divide treatment groups into "high" or "low" exposure and to determine the relationship between length of drug exposure and long-term outcomes. The use of MPR reduces the bias introduced in long-term trials by the tendency of patients who are doing well on therapy stay on therapy and for patients who are doing poorly to stop a particular therapy. Other statistical approaches including Propensity Scoring were used to control for other known sources of bias.(1) The study, sponsored by Bayer HealthCare Pharmaceuticals, is the longest follow-up of a registrational MS trial cohort. Longitudinal data from 372 patients, collected 16 years after the start of the registrational trial, were used to develop an analytical strategy to investigate the relationship between timing of drug initiation and exposure and long-term outcomes.

INDICATIONS AND USAGE

BETASERON (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

IMPORTANT SAFETY INFORMATION

The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% o
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Innerscope Research(TM) Names Caleb Siefert as Senior Scientist to Lead Companys Statistical Analyses and Study Designs
2. Tissue analyses indicate survival benefits for some lung cancer patients
3. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
4. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
5. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
6. 16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nations Leading Providers for Saving His Life
7. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
8. Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009
9. Follow-Up Tests of Leading Personal Care and Household Cleaning Brands Reveal Improvements in Levels of Carcinogenic 1,4-dioxane
10. Follow-Up Tests of Leading Personal Care and Household Cleaning Brands Reveal Significant Improvements in Levels of Carcinogenic 1,4-dioxane
11. National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... traces roots of the problem , , THURSDAY, June 19 ... the use of an oral rapid HIV test was ... Health and Mental Hygiene, which operates 10 sexually transmitted ... introduced on-site, rapid HIV testing of finger-stick, whole-blood specimens ...
... 2008) Health-care system constraints combined with a lack ... brokering which patients are in greatest need of hip ... Michael,s Hospital researcher funded by the Canadian Institutes of ... means not everyone who needs this surgery will actually ...
... Chief of Naval Research (CNR) Rear Admiral William E. Landay ... brought to the Office of Naval Research (ONR) during the ... at the Marriott Wardman Park Hotel in Washington, D.C. , ... and technology organization, recognized both inside and outside the Navy, ...
... AUBURN HILLS, Mich., June 19 ... software for the manufacturing,enterprise, today announced the ... Plexus Online to facilitate collaboration,coordination and information-sharing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ), ...
... As if the emotional and financial impact of ... health problems. H. James Wedner, M.D., professor of medicine ... at Washington University School of Medicine in St. Louis, ... are fertile grounds for mold growth, which can cause ...
... reap rewards for people with asthma, MS, scientists ... have uncovered cellular proteins that may be key to ... study. , The findings, performed so far only ... range of human diseases that are mediated by immune ...
Cached Medicine News:Health News:False Positives in Oral HIV Test Halt Use in NYC 2Health News:System constraints forcing Canadian physicians to become medical brokers in prioritizing 2Health News:ONR offers up to $1M for innovative science and technology ideas 2Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 2Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 3Health News:Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute 4Health News:Allergy expert has advice for flood victims 2Health News:Allergy expert has advice for flood victims 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 4
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
... rede phines sharpness and efficiency with ... penetrating keratoplasty. Advanced trephine blade technology ... achieve the critical fit needed for successful ... customized system enables surgeons to select the ...
Medicine Products: